Latest Updates of Companies in the Immunohistochemistry Market
| Company | Headquarters | Latest Update |
| Abcam | United States | In April 2026, Abcam, a Danaher company and a global provider of validated antibodies and assay solutions, announced SimpleStep Ignite ELISA, a next-generation chemiluminescent immunoassay platform intended for researchers who require rapid and higher-quality decisions |
| Bio-Rad Laboratories, Inc. | United States | Bio-Rad has expanded its portfolio of recombinant monoclonal anti-idiotypic antibodies and SpyCatcher reagents, enhancing support for bioanalytical assay development and antibody drug research. |
| Merck KGaA | Germany | Merck offers an incessantly increasing, ISO-certified catalog of primary antibodies designed particularly for immunohistochemistry (IHC) on formalin-fixed, paraffin-embedded (FFPE) tissues. |
| Agilent Technologies, Inc. | United States | In March 2026, Agilent Technologies, a search organization, entered into a definitive agreement to acquire Biocare Medical, a worldwide leader in clinical pathology services, for $950 million in an all-cash transaction. |
| Thermo Fisher Scientific Inc. | United States | Thermo Fisher offers a advance suite of tools to allow deeper, more particular, and highly multiplexed tissue analysis. |
Recent Developments in the Immunohistochemistry Market
- In April 2026, Leinco Technologies, a leader in antibody and protein development, and CellCarta, a worldwide provider of precision medicine laboratory services, are pleased to announce a strategic partnership aimed at advancing proteomics services that advance the development of immuno-oncology and other targeted therapeutic modalities.
- In March 2026, Biocare Medical, a provider of immunohistochemistry (IHC) and in situ hybridization (ISH) reagents and staining platforms, announced a strategic co-exclusive distribution collaboration with PreciPoint GmbH, a developer and manufacturer of compact digital pathology services for modern pathology laboratories.
Supply Chain Analysis
R&D:
- Research and development (R&D) in immunohistochemistry involves target identification and assay conception, main antibody selection and screening, significant antibody selection and screening, identification processes optimization, validation, and reproducibility testing, and clinical or assay translation
- Key Players: Merck KGaA and Bio-Rad Laboratories, Inc.
Manufacturing Processes:
- Major immunohistochemistry manufacturing processes are biological reagent manufacturing, tissue processing, sample preparation, and staining protocol.
- Key Players: Thermo Fisher Scientific Inc. and Agilent Technologies, Inc.
Patient Services:
- Patient services are offered by doctors to diagnose conditions precisely, determine disease severity, and personalize targeted treatments, particularly in oncology.
- Key Players: F. Hoffmann-La Roche Ltd. and Danaher Corporation
Market Growth
The global immunohistochemistry market size was estimated at USD 3.42 billion in 2025 and is predicted to increase from USD 3.73 billion in 2026 to approximately USD 8.05 billion by 2035, expanding at a CAGR of 8.94% from 2026 to 2035.
Keypoints
- Company Overview
- Locations Subsidiaries/Geographic reach
- Key Executives
- Company Financials
- Patents registered
- SWOT Analysis
- Applications Catered
- Strategic collaborations
- Recent Developments
- Competitive Benchmarking